FOOD AND DRUG ADMINISTRATION (FDA) Center for Drug Evaluation and Research (CDER)

Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) using International Council for Harmonisation (ICH) E2B(R3) Standards

Silver Spring Civic Building at Veterans Plaza The Buffalo Soldiers Great Hall One Veterans Place Silver Spring, MD, 20993

March 25, 2019

AGENDA

Meeting Website: https://www.fda.gov/Drugs/NewsEvents/ucm621215.htm
Docket No. FDA-2018-N-4002

9:00 am 9:20 am	Introductions Session 1: FAERS II and E2B R3	Suranjan De, MS, MBA Deputy Director Regulatory Science Staff Office of Surveillance & Epidemiology CDER, FDA Suranjan De, MS, MBA
	Up Versioning Plans	Deputy Director, RSS FDA
9:50 am	Session 2: Electronic submission of IND safety reporting Background	Meredith Chuk, MD Acting Associate Director of Safety Office of Hematology and Oncology Products Office of New Drugs CDER, FDA
10:00 am	Implementation plans, Regional requirements using E2BR2, and Case examples	Meredith Chuk, MD Acting Associate Director of Safety, OHOP FDA
10:50 am	Questions	Meredith Chuk, MD Acting Associate Director of Safety, OHOP FDA
11:00 am	Break	
11:15 am	Up versioning to ICH E2B R3 – Regional requirements	Ta-Jen Chen, MS Project Manager Office of Strategic Programs CDER, FDA
12:00 pm	Lunch (on your own)	
1:00 pm	Session 3: Electronic submission of Post-market safety reporting	Suranjan De, MS, MBA Deputy Director, RSS FDA

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Electronic Submission of Adverse Event Reports to FDA Adverse Event Reporting System (FAERS) using International Council for Harmonisation (ICH) E2B(R3) Standards

March 25, 2019

AGENDA (cont.)

		T
1:10 pm	Up versioning to ICH E2B R3 – Regional requirements	Suranjan De, MS, MBA Deputy Director, RSS FDA
1:40 pm	Backward Forward Compatibility	Suranjan De, MS, MBA Deputy Director, RSS FDA
2:10 pm	Break	
2:20 pm	Session 4: Updates on electronic submission routing mechanisms and methods	Suranjan De, MS, MBA Deputy Director, RSS FDA
2:50 pm	Session 5: E2B R3 implementation – Industry experience with Regulators	TBD
3:50 pm	Summary and closing remarks	Suranjan De, MS, MBA Deputy Director, RSS FDA
4:00 pm	Adjourn	

For more meeting information, visit the Meeting Website: https://www.fda.gov/Drugs/NewsEvents/ucm621215.htm